↓ Skip to main content

Dove Medical Press

Article Metrics

Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience

Overview of attention for article published in OncoTargets and therapy, December 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
1 tweeter
googleplus
1 Google+ user

Readers on

mendeley
8 Mendeley
Title
Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience
Published in
OncoTargets and therapy, December 2015
DOI 10.2147/ott.s93939
Pubmed ID
Authors

Lin Zhong, Pusen Wang, Hao Li, Baojie Shi, Jianning Wang, Chunguang Wang

Abstract

Liver transplantation (LT) offers the most effective treatment for hepatocellular carcinoma patients. Various preoperative variables are correlated with survival after LT, but the prognostic role of aging on LT remains controversial. Between January 2001 and December 2011, 290 consecutive transplants for patients with hepatocellular carcinoma performed in Shanghai First People's Hospital (People's Republic of China) were analyzed retrospectively. We compared patient characteristics and survival curves between a younger group (less than 49 years, n=135) and an aged group (50 years or older, n=155). We then performed Cox multivariate regression analysis of the risk factors for survival in aged and younger patients. Younger age was associated with higher alpha-fetoprotein (P=0.014), larger tumor size (P=0.038), poorer differentiation (P=0.025), portal lymph node metastasis (P=0.001), and higher recurrence rate (P=0.038). Aged patients had significantly longer recurrence-free survival and overall survival (P=0.020 and P=0.014, respectively); however, there were no significant differences between the younger and aged patients who met the Milan criteria (P>0.05). The 1-, 3-, and 5-year recurrence-free survival rates were 59.7%, 44.5%, and 37.3%, respectively, in the younger group, and 67.9%, 55.3%, and 53.8%, respectively, in the aged group. The 1-, 3-, and 5-year overall survival rates were 68.4%, 45.5%, and 38.9%, respectively, in the younger group, and 76.1%, 59.7%, and 53.9%, respectively, in the aged group. Alpha-fetoprotein ≥400 ng/mL, microvascular invasion, and tumor size >5 cm were independent risk factors for prognosis in both groups. Younger patients in our center tended to present with more aggressive tumors and have a higher risk of recurrence. Our single-center experience suggests that younger patients should be assessed more rigorously before LT, while aged patients should be actively considered for LT after appropriate selection.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 13%
Unknown 7 88%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 25%
Researcher 2 25%
Student > Ph. D. Student 1 13%
Student > Master 1 13%
Unknown 2 25%
Readers by discipline Count As %
Medicine and Dentistry 4 50%
Unknown 4 50%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2016.
All research outputs
#3,172,949
of 6,897,266 outputs
Outputs from OncoTargets and therapy
#179
of 816 outputs
Outputs of similar age
#135,222
of 292,578 outputs
Outputs of similar age from OncoTargets and therapy
#29
of 214 outputs
Altmetric has tracked 6,897,266 research outputs across all sources so far. This one has received more attention than most of these and is in the 51st percentile.
So far Altmetric has tracked 816 research outputs from this source. They receive a mean Attention Score of 1.3. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,578 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 214 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.